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Motivational, proteostatic 
and transcriptional deficits 
precede synapse loss, gliosis 
and neurodegeneration in the 
B6.HttQ111/+ model of Huntington’s 
disease
Robert M. Bragg1, Sydney R. Coffey1, Rory M. Weston1,2, Seth A. Ament3,4, Jeffrey P. Cantle1, 
Shawn Minnig1, Cory C. Funk3, Dominic D. Shuttleworth1, Emily L. Woods1, 
Bonnie R. Sullivan1, Lindsey Jones1, Anne Glickenhaus1, John S. Anderson1, 
Michael D. Anderson1, Stephen B. Dunnett5, Vanessa C. Wheeler6, Marcy E. MacDonald6, 
Simon P. Brooks5, Nathan D. Price3 & Jeffrey B. Carroll1,6
We investigated the appearance and progression of disease-relevant signs in the B6.HttQ111/+ mouse, 
a genetically precise model of the mutation that causes Huntington’s disease (HD). We find that 
B6.HttQ111/+ mice are healthy, show no overt signs of central or peripheral inflammation, and no gross 
motor impairment as late as 12 months of age. Behaviorally, we find that 4–9 month old B6.HttQ111/+ 
mice have normal activity levels and show no clear signs of anxiety or depression, but do show clear 
signs of reduced motivation. The neuronal density, neuronal size, synaptic density and number of glia is 
normal in B6.HttQ111/+ striatum, the most vulnerable brain region in HD, up to 12 months of age. Despite 
this preservation of the synaptic and cellular composition of the striatum, we observe clear progressive, 
striatal-specific transcriptional dysregulation and accumulation of neuronal intranuclear inclusions 
(NIIs). Simulation studies suggest these molecular endpoints are sufficiently robust for future preclinical 
studies, and that B6.HttQ111/+ mice are a useful tool for modeling disease-modifying or neuroprotective 
strategies for disease processes before the onset of overt phenotypes.
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion 
of a glutamine-coding CAG trinucleotide repeat near the 5’ end of the HTT gene1. The identification of the 
disease-causing mutation did not point to an obvious set of therapeutic approaches, given that the huntingtin pro-
tein is a very large HEAT/HEAT-like repeat solenoid scaffold2, which is highly evolutionarily conserved, and vital 
to normal development3. A key effort in preclinical HD research is understanding the link between polyglutamine 
expansion in huntingtin and the selective cellular toxicity in corticostriatal circuits which is thought to cause dis-
ease symptoms. A range of animal models of the HD mutation have been developed to investigate this question, 
including knock-in and transgenic mice as well as transgenic rats, sheep, pigs and nonhuman primates4. Unique 
amongst described models, knock-in mice with varying allele sizes provide the ability to quantitatively study the 
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relationship between CAG size and pathogenesis in an otherwise isogenic system5. Recent molecular6 and behav-
ioral7 analyses of an allelic series of HD knock-in mice reveal very discrete CAG-dependent disease signatures, 
suggesting these mice recapitulate a cardinal feature of human HD, namely the relationship between CAG tract 
length and the rapidity of disease progression3,8. Because knock-in models express Htt at endogenous levels from 
the endogenous locus they precisely mimic the genetics of human HD, however their use in preclinical studies has 
been limited because their overt neurological signs are very subtle compared to transgenic animals9,10. The bulk 
of preclinical research has therefore been conducted in transgenic models expressing either full-length or short 
fragments of mutant huntingtin, which display more phenotypes11.
The embracing of transgenic models by the field has largely been driven by the desire to model important signs 
and symptoms of HD, including progressive striatal atrophy and hyperkinetic motor disturbances. We consider 
that these phenomena emerge from a substrate of decades of progressive cellular and physiological dysfunction 
before manifesting in human patients as a set of clinical signs recognizable as “Huntington’s disease”12. Targeting 
these late features of the disease process, including cell death and emergent motor symptoms, may enable the 
modification of late HD symptoms. However, this strategy doesn’t allow targeting of the earliest disease changes 
that precede overt clinical disease features, which if clearly identified might ultimately provide paths to preven-
tion and/or early-stage reversal. Finally, no HD mouse model develops chorea-like hyperkinetic movements, and 
mouse models present with modest striatal volume loss over the lifespan of the mouse13,14, while human disease 
results in the nearly complete atrophy of this critical structure15.
We and others acknowledge that knock-in mouse models of HD cannot fully recapitulate clinical symptoms 
that, in human mutation carriers, require approximately four decades of pathogenic processes to emerge and are 
followed by a further 15 years to progress to death16. However, these genetically faithful but subtle mouse models 
provide us the ability to study the earliest and subtlest changes caused by the CAG expansion of Htt - the very 
processes we wish to understand if we are to develop interventions to prevent the development of clinical HD 
onset, rather than addressing its symptoms only after significant damage to key processes has been incurred. 
Towards this end, we have here characterized the earliest observable changes in the murine B6.HttQ111/+ (here-
after HttQ111/+) model of the HD mutation17. Since their creation, these mice have been utilized to test specific 
hypotheses in a wide range of studies18, and a single unbiased phenotypic screen10, but have not been well char-
acterized as a system for conducting preclinical studies. We therefore examined the incidence, progression and 
statistical power of a range of phenotypes in these mice, and find that they provide a powerful tool for studying 
hypotheses about the early disease events that stem from the HD CAG expansion mutation. We observe robust 
transcriptional, proteostatic and motivational phenotypes which progress from 3 to 12 months of age in HttQ111/+ 
mice. Simulation studies suggest interventions that rescue specific signs by 10–25% are readily detectable in 
appropriately powered preclinical studies, making the HttQ111/+ mouse a useful tool for testing disease modifying 
therapeutics in HD.
Results
General Animal Health and Inflammation. Consistent with previous reports of HttQ111/+ mice on the 
CD1 and B6J strains9,10, no body weight changes were observed between 3 and 12 months of age (effect of gen-
otype, F(1,94) = 3.1, p = 0.07, mean CAG length = 113, cohort summary in Table 1). Important plasma chemistry 
parameters, including protein, glucose and ion concentrations, as well as liver enzyme levels, were normal at 4 
months of age in HttQ111/+ mice10. Because we are interested in progressive phenotypes, we examined a suite of 
clinical chemistry parameters at 12 months of age - no changes were observed in any of these parameters in male 
HttQ111/+ mice at this age (Table 2). Consistent with findings in younger mice, and coupled with body weight 
observations, these results suggest that up to 12 months of age HttQ111/+ mice are grossly healthy. Subtle increases 
in concentrations of pro-inflammatory chemokines and cytokines have been observed in presymptomatic HD 
mutation carriers19 and some (e.g. YAC128), but not all (e.g. BACHD), transgenic HD mice by 12 months of 
age20. To understand whether increased peripherally-detectable inflammation is occurring in HttQ111/+ mice we 
quantified cytokines, chemokines and acute phase reactants in the plasma of 12-month-old, male HttQ111/+ mice 





3 Months M B6.Htt+/+ 9 24.3 (1.7)
3 Months M B6.Htt Q111/+ 9 113 (3.3) 23.8 (1.4)
3 Months F B6.Htt+/+ 9 18.2 (0.7)
3 Months F B6.Htt Q111/+ 9 114 (2.5) 17.2 (1.4)
9 Months M B6.Htt+/+ 9 28.2 (1.8)
9 Months M B6.Htt Q111/+ 9 113 (5.0) 31.4 (1.8)
9 Months F B6.Htt+/+ 9 23.3 (1.2)
9 Months F B6.Htt Q111/+ 9 113 (3.3) 23.5 (1.6)
12 Months M B6.Htt+/+ 9 30.6 (2.6)
12 Months M B6.Htt Q111/+ 9 N/A 31.4 (1.6)
12 Months F B6.Htt+/+ 9 25.2 (3.7)
12 Months F B6.HttQ111/+ 9 N/A 26.1 (2.5)
Table 1.  Cohort 2 characteristics.
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(multi-analyte profiling, Myriad RBM). We successfully quantified 16 of these molecules (Table 2: Eotaxin, EGF, 
IP-10, IL-1β, IL-18, LIF, M-CSF-1, MDC, MIP-1α, MIP-3β, MCP-1, MCP-3, MCP-5, Thrombopoietin, TIMP-1, 
VEGF-A) but observed no changes in 12-month-old HttQ111/+ mice. Other important pro-inflammatory mol-
ecules (FGF9, FGF-basic, GM-CSF, KC/GRO, IFN-γ, IL-1α, IL-2, −3, −5, −6, −7, −10, −11, −12p70, −17a, 
MIP1-β, OSM, SCF, and TNF-α) were also assayed, but fell below the indicated limit of detection in all mice 
studied (lower limit of quantification, LLoQ, provided in Table 2). These data suggest that peripherally-detectable 
immune activation is either not occurring in 12-month-old, male HttQ111/+ mice, or is sufficiently subtle to be 
missed by these analyses.
Striatal Transcriptional Alterations. Altered transcription is an early and prominent feature of HD 
pathology, and is observed in both animal models and samples from human patients12. Because we are inter-
ested in intervening at the earliest possible point in the pathogenic process, we investigated the time course of 
transcriptional changes in the central nervous system of HttQ111/+ mice. As an initial, untargeted pilot study, 
Analyte Units +/+(SD) Q111/+ (SD) T-test
EGF pg/mL 201 (31.7) 211 (24.6) 0.64
Eotaxin pg/mL 2170 (1044) 1368 (173) 0.18
IL-1 beta ng/mL 8.975 (2.1) 9.45 (1.3) 0.71
IL-18 ng/mL 20.8 (4) 25.3 (1.5) 0.08
IP-10 pg/mL 60 (42.2) 64.5 (19.8) 0.85
LIF pg/mL 915.3 (173.6) 722.8 (129.3) 0.13
MCP-1 pg/mL 55.5 (28.9) 43 (17.6) 0.49
MCP-3 pg/mL 293.5 (195.4) 204.8 (30.2) 0.4
MCP-5 pg/mL 17.7 (7.5) 16.5 (3.3) 0.78
M-CSF-1 ng/mL 3.45 (1.1) 4.3 (0.2) 0.19
MDC pg/mL 2157.5 (1099.5) 1470 (216.9) 0.27
MIP-1 alpha ng/mL 5.4 (0.8) 5.4 (0.5) 1
MIP-3 beta ng/mL 3.3 (0.6) 2.5 (0.2) 0.05
Thrombopoietin ng/mL 35 (7.7) 37.5 (5.2) 0.61
TIMP-1 ng/mL 1.4 (1) 1.15 (0.1) 0.65
VEGF-A pg/mL 185.5 (28.4) 192.5 (27.8) 0.74
Glucose mg/dl 253.3 (20.6) 238.2 (85.4) 0.74
BUN mgld 22.8 (4.2) 23 (4.5) 0.93
Creatine mg/ld 0.05 (0.05) 0.02 (0) 0.4
Phosphate mg/dl 6.45 (0.1) 7.68 (1.1) 0.06
Total Protein g/dl 3.5 (0.1) 3.4 (0.2) 0.48
Albumin g/dl 2 (0.01) 1.94 (0.1) 0.41
Globulin g/dl 1.5 (0.05) 1.46 (0.1) 0.82
Albumin/Globulin Ratio 1.4 (0.06) 1.34 (0.2) 0.91
Total Bilirubin mg/dl 0.1 (0) 0.18 (0.2) 0.41
ALP U/L 0.75 (0.5) 0.8 (0.4) 0.88
GGT U/L 1 (0.8) 1.2 (0.4) 0.65
ALT U/L 33 (11.4) 40.4 (24.4) 0.6
AST U/L 60 (17.6) 78.6 (32.4) 0.34
Cholesterol mg/dl 54.5 (11.2) 56.2 (15) 0.86
Table 2.  Clinical chemistry parameters are normal in 12 month old HttQ111/+ mice. Top level analytes are 
from inflammationMAP (Myriad RBM, Austin, TX, USA), lower level analytes are from clinical chemistry 
panel (Phoenix Central Labs, Mukilteo, WA, USA). Abbreviations: epidermal growth factor (EFG), interleukin 
(IL), interferon gamma-induced protein (IP), monocyte chemoattractant protein (MCP), macrophage colony-
stimulating factor (M-CSF), macrophage-derived chemokine (MDC), macrophage inflammatory proteins 
(MIP), tissue inhibitor of metalloproteinase (TIMP), vascular endothelial growth factor-A (VEGF-A), 
alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate 
aminotransferase (ASP). Inflammation markers measured below LLoQ (LLoQ listed): Fibroblast growth factor 
(FGF)−9 (2.4 ng/mL), FGF-basic (9.6 ng/mL), granulocyte-macrophage colony-stimulating factor (15 pg/mL), 
keratinocyte chemoattractant/human growth-regulated oncogene (0.028 ng/mL), interferon gamma (182 pg/mL), 
IL-1 alpha (100 pg/mL), IL-2 (70 pg/mL), IL-3 (5.9 pg/mL), IL-4 (60 pg/mL), IL-5 (0.6 ng/mL), IL-6 (4.7 pg/mL), 
IL-7 (0.19 ng/mL), IL-10 (125 pg/mL), IL-11 (56 pg/mL), IL-12p70 (0.091 ng/mL), IL-17A (0.018 ng/mL), MIP-1 
beta (142 pg/mL), MIP-2 (11 pg/mL), oncostatin-M (0.24 ng/mL), stem cell factor (652 pg/mL), tumor necrosis 
factor-alpha (0.082 ng/mL). N = 4 male HttQ111/+, 4 male Htt+/+, subset of 12-month mice from Table 1).
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we examined striatal and cerebellar genome-wide transcriptional changes in 3- and 9-month-old HttQ111/+ mice 
using mRNA sequencing (RNASeq). At 3 months of age, no robust transcriptional alterations were detected in 
the striatum of HttQ111/+ mice compared to wild-type mice (Fig. 1a, 5 quantified transcripts - Lct, Zfp385c, Smpx, 
Dsp, Crlf1 - have an effect of genotype with a false discovery rate (FDR) of < 5%). By 9 months of age, 726 tran-
scripts were changed in the striatum of HttQ111/+ mice compared to wild-type mice (Fig. 1a, 245 up-regulated, 481 
down-regulated at FDR < 5%). The cerebellum, despite robustly expressing mutant Htt21–23, is relatively spared 
from pathological tissue loss in human HD patients24 and the YAC128 mouse model of HD14. We therefore com-
pared the rate and scale of transcriptional dysregulation between the cerebellum and striatum of HttQ111/+ mice 
at 3 and 9 months of age. There were very few significant effects of CAG expansion in Htt in the cerebellum at 
either age (Fig. 1a, 3 genotype-sensitive transcripts, 2 down-regulated, 1 up-regulated at FDR < 5%). These data 
confirm that, as in humans with HD and other animal models, progressive striatal transcriptional dysregulation 
is a feature of aging HttQ111/+ mice.
We next examined pathway enrichment of dysregulated transcripts using both hypergeometric25 and gene set 
enrichment analysis (GSEA)26 techniques. The hypergeometric test examines over-enrichment of differentially 
expressed genes in a specific pathway, while GSEA quantifies whether a set of pathway genes is over-represented 
at the top or bottom of an ordered list of genes - here, the full list of 9-month striatal transcripts, ordered by the 
fold-change in HttQ111/+ mice compared to wild-type mice. Hypergeometric testing of 726 genotype-sensitive 
(FDR < 5%) striatal transcripts (from a gene universe of 19,031 robustly assayed genes) revealed significant 
enrichment of striatal genotype-sensitive transcripts in 8 pathways with an adjusted p-value < 0.05, notably in 
neuronal signaling pathways (Fig. 1b). GSEA revealed 15 gene sets significantly enriched (FDR < 0.1) at the high 
or low end of the list of striatal transcripts, ordered by their genotype expression ratio (HttQ111/+/Htt+/+; Fig. 1c). 
Figure 1. Progressive, striatal-specific, transcriptional dysregulation in the aging HttQ111/+ brain. (a) The 
impact of genotype on the expression level of each of the 19,031 transcripts assayed is indicated - statistical 
significance on the y-axis (-log10 FDR), and fold-change on the x-axis (log fold-change, HttQ111/+/Htt+/+). Color 
indicates statistical significance - black indicates FDR > 0.1, red and blue indicate FDR < 0.1 for up- and down-
regulated genes in the HttQ111/+ striatum, respectively. (b) Network diagram depicting the 8 reactome pathways 
with adjusted p-values less than 0.05 in a hypergeometric analysis, and the proportion of genes shared between 
each pathway. The size of each node corresponds to the overall gene set size (e.g. signaling by GPCR pathway 
includes 853 genes, Gαz signalling events 44), while the width of the edges corresponds to the Jaccard similarity 
coefficient for the pair of gene sets (the intersection of the two sets divided by its union). (c) Network diagram 
depicting the 15 reactome pathways whose genes are non-randomly distributed on the ordered list of striatal 
transcripts with an FDR < 0.1, and the proportion of genes shared between each pathway. Blue nodes indicate 
down-regulated pathways, while red nodes indicate upregulation in the 9 month old HttQ111/+ striatum.
www.nature.com/scientificreports/
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Nineteen common pathways had nominal enrichment p-values < 0.05 in both GSEA and hypergeometric analy-
ses, including Reactome pathways involved in neurotransmission and cellular signaling (e.g. transmission across 
chemical synapses, neuronal system, signaling by GPCR, and GPCR downstream signaling; Table S1), suggesting 
synaptic and signaling transcripts are altered at the transcriptional level in the 9-month-old HttQ111/+ striatum.
To orthogonally validate the observed striatal transcriptional alterations and examine their relevance 
as useful preclinical tools in HttQ111/+, we quantified specific transcript levels in the striatum of 3-, 9- and 12- 
month-old HttQ111/+ mice using quantitative real-time polymerase chain reaction (QRT-PCR). As predicted 
by cross-sectional RNASeq data (Fig. 1), transcript levels of the critical striatal signaling gene Ppp1r1b, that 
encodes the protein dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP32) are normal in 
HttQ111/+ mice at 3 months of age, but reduced at both 9 and 12 months of age (effect of genotype F(1,47) = 6.74, 
p = 0.01, Figure 2a). Similarly, we find that levels of a suite of additional neuronal signaling and synaptic genes 
(including: Cnr1, Drd2, Homer1, Pde10a, Penk, Scn4b) are reduced in aged (9- and 12-month-old) but not young 
(3-month-old) HttQ111/+ mice (Fig. 2a, effect sizes for each target shown in Fig. 2b). Other transcripts increase 
over time in HttQ111/+ and include genes involved in DNA damage (e.g. N4bp2) or immune response (e.g. Islr2, 
H60b, Fig. 2a). These results confirm the findings of our RNAseq study and suggest that levels of a range of tran-
scripts are sensitive genotype markers in the aging HttQ111/+ striatum.
Striatal Histology. We also considered a range of histological endpoints in the dorsolateral striatum of 3-, 
9- and 12-month-old HttQ111/+ mice. Compared to tissue-level analyses such as RNASeq and QRT-PCR, immu-
nohistochemistry (IHC) enables the identification of specific cell types and analysis of subcellular localization. 
First, a trivial explanation for the observed transcriptional alterations in the striatum of the HttQ111/+ mice is 
that the cellular composition or relative cell sizes within the striatum has changed. To examine this possibility, 
we counted putative neurons, astrocytes and microglia in the dorsolateral striatum (respectively: NeuN-, glial 
fibrillary acidic protein- and allograft inflammatory factor 1-immunoreactive cells). Between 3–12 months of 
age, the neuronal density in the dorsolateral striatum of HttQ111/+ mice does not change (Fig. 3a, F(1, 100) = 0.03, 
p = 0.87), nor does the cross-sectional area of NeuN-immunoreactive soma in the dorsolateral striatum at 9 
months (NeuN-immunoreactive cell size distributions shown in Fig. 3b, two-sample Kolmogorov-Smirnov (K-S) 
test D = 0.02, p = 0.9). We next quantified astrocytic and microglial density in the dorsolateral striatum of 12 
month old HttQ111/+ and Htt+/+ mice, finding that neither is increased in 12 month old HttQ111/+ mice (Fig. 3d). 
Progressive loss of synaptophysin density has been reported in transgenic HD and other neurodegenerative dis-
ease mouse models27. We quantified synaptophysin density in the dorsolateral striatum and find that HttQ111/+ 
and Htt+/+ mice have equivalent levels of synaptophysin staining from 3–12 months of age (Fig. 3c, F(1, 93) = 3.71, 
p = 0.057). These results suggest that the robust transcriptional alterations we observe in the aging HttQ111/+ stri-
atum (Fig. 1) are not due to altered numbers or size of neurons, loss of synaptic compartments and that overt 
gliosis is not a component of the phase of HD modeled by the HttQ111/+ mice.
We also examined the appearance of aggregated striatal huntingtin using the MW8 antibody, which detects 
aggregated, but not diffuse, mutant huntingtin28, but to our knowledge has not yet been applied to study 
HttQ111/+ mice. We restricted our analyses to neuronal cell bodies, immunoreactive for NeuN, a well-described 
pan-neuronal marker29. In the dorsolateral striatum of 3-month-old HttQ111/+ mice there is virtually no neuronal 
MW8 immunoreactivity, but by 9 months of age we observe robust accumulation of both small punctate and 
large inclusion staining in neuronal nuclei (Fig. 4a). Between 9 and 12 months of age, increased levels of neu-
ronal intranuclear inclusions (NII) in the HttQ111/+ striatum are accompanied by a reduction in the total nuclear 
MW8 immunoreactivity. Total neuronal nuclear MW8 immunoreactivity increases from 3 to 9 months of age, 
before declining at 12-months of age (Kruskal-Wallis: H(5) = 80.7, p < 0.0001, Dunn: 3-month genotype p = 0.15, 
9-month genotype p < 0.0001, 12-month genotype p < 0.0001; Fig. 4b). This rise and fall in total neuronal nuclear 
MW8 immunoreactivity is accompanied by a progressive increase in the percentage of cells with large NIIs, 
from 0% at 3-months to 13% at 9-months and 28% by 12 months of age (Kruskal-Wallis: H(5) = 87.9, p < 0.0001, 
Dunn: 3-month genotype p = 1, 9-month genotype p < 0.0001, 12-month genotype p < 0.0001, Fig. 4c). In par-
allel, the average size of striatal NIIs in HttQ111/+ mice increases more than 40% from 1.3 ± 0.7 μm at 9 months 
to 1.8 ± 0.9 μm at 12 months of age (two-sample K-S test, D = 0.29, p < 0.0001). Impaired autophagy has been 
proposed to contribute to impaired proteostasis in HD29,30, and in the brain mHTT interacts directly with p62/
Sqstm1, an autophagic receptor protein important for selective macroautophagy31. We observed complete 
co-localization between p62 and MW8 immunoreactivity in striatal NII’s in HttQ111/+ mice (Fig. 4d) suggesting 
that, as has been observed in cell culture31, p62 is found in NIIs. We finally considered whether quantitative 
IHC for specific MSN targets is superior to QRT-PCR quantification. As a proof of concept, we quantified neu-
ronal DARPP32 levels in corticostriatal sections. Consistent with mRNA reductions (Fig. 2), we observe reduced 
neuronal somatic DARPP32 levels in the HttQ111/+ striatum (Fig. 5; Kruskal-Wallis: H(5) = 19.6, p = 0.0015, 
Dunn: 3-month genotype p = 0.12, 9-month genotype p = 0.09, 12-month genotype p = 0.006). We find that, 
for DARPP32, quantification of IHC data is more variable than QRT-PCR when establishing reductions in the 
HttQ111/+ striatum.
Behavioral Analyses. We cross-sectionally analyzed behavior in several cohorts of 3–9 month old HttQ111/+ 
mice, including assays of motivation, anhedonia, depression, and anxiety (cohorts described in methods). We 
first measured reward seeking behavior in HttQ111/+ mice using an operant fixed ratio 1 (FR1) behavioral assay to 
examine how many sweet rewards mice will perform for in a 5 minute block at 6 months of age. We found that 
HttQ111/+ mice demonstrate reduced reward attainment relative to Htt+/+ mice (Fig. 6a; Genotype: F(1,14) = 17.0, 
p = 0.001: Genotype x Reward Size: F(2,28) = 8.4, p = 0.001). In an attempt to discern hedonic from motivational 
explanations for this reduced reward attainment, we examined preference for either 2% or 4% sucrose in drinking 
water in a separate cohort of mice. We found no difference between 9 month old Htt+/+ and HttQ111/+ mice (2% 
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Figure 2. Confirmation of progressive transcriptional dysregulation in the striatum of aging HttQ111/+ 
mice using quantitative real-time polymerase chain reaction. (a) Guided by transcriptional discovery 
with RNAseq, we quantified a number of transcripts and found that many synaptic and neuronal signalling 
transcripts were down as mice aged from 3-months to 9- and 12- months. As anticipated, we also found 
upregulated transcripts related to immune and DNA damage pathways (N = 60, subset of 5 mice per row 
from Table 1). Data are presented as boxplots. (b) Corresponding longitudinal effect sizes for each transcript 
(highlighted in colored bands above) are displayed in the same color below, with whiskers representing the 
95% confidence interval range. Along the x-axis, transcripts are ordered by increasing effect size at 12-months, 
though robust effects are seen at both 9- and 12-months. Our results demonstrate that these transcripts are 
sensitive genotype markers that make suitable targets for assessing rescue in interventional trials using the 
HttQ111/+ mouse model.
www.nature.com/scientificreports/
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sucrose Genotype x Sucrose concentration: F(1,38) = 0.03, p = 0.87; 4% sucrose Genotype x Sucrose concentration: 
F(1,35) = 0.41, p = 0.53, Figure S1). However, we did find HttQ111/+ mice demonstrate a stronger preference for 
sucrose pellets (Genotype: F(1,14) = 15.9, p = 0.001, Fig. 6b). Taken together, these tests demonstrate no inherent 
lack of sucrose preference in HttQ111/+ mice that is present in Htt+/+ mice.
To explore the potential contributions of anxiety or depression to the observed reward attainment changes we 
conducted several tests of these phenotypes in a separate cohort of 9-month old Htt+/+ and HttQ111/+ mice. First 
we conducted the Porsolt swim test, a measure of behavioral despair30, where we observe no differences between 
9-month old Htt+/+ and HttQ111/+ mice in the duration of time spent inactive during the task (Fig. 6c; t(38) = 0.8, 
p = 0.9). Similarly, using the elevated plus maze task as a measure of anxiety32, we found that 9-month-old Htt+/+ 
and HttQ111/ mice do not differ in the amount of time spent in the open arms (Fig. 6d; t(37) = 0.7, p = 0.5), or in 
the percentage of total arm entries into the open arms, (t(37) = −1.3, p = 0.2). As a final measure of anxiety levels 
in HttQ111/+ mice, we also employed the light/dark exploration task 32,33, finding that Htt+/+ and HttQ111/+ mice 
spend the same amount of time in the light and dark halves of the apparatus (Fig. 6e; t(38) = 0.04, p = 0.9) and 
enter the light compartment of the maze a similar number of times (t(38) = −0.6, p = 0.5). Altogether, these data 
suggest that up to 9-months of age HttQ111/+ mice do not display anxiety-related or depressive-like symptoms, and 
declines observed in reward seeking behavior may reflect presently undefined cognitive or motivational issues 
worthy of additional study.
Power Analysis for preclinical studies in HttQ111/+ mice. To establish the utility of the natural history 
data collected here (QRT-PCR and IHC), we conducted several power analysis studies to understand whether 
these results would be useful in a preclinical trial setting. We considered a hypothetical 2 × 2 factorial experiment, 
with two genotypes (Htt+/+vs. HttQ111/+) and two treatment groups (baseline vs. a hypothetical treatment). We 
simulated data for Htt+/ and HttQ111/+ mice in the ‘treatment’ condition by drawing values from a random nor-
mal distribution with the same mean, variance, and covariance as our real natural history data. Assuming a 50% 
rescue from a hypothetical intervention, we established the power of single molecular endpoints in a preclinical 
Figure 3. No evidence of changes in striatal cell distribution, neuronal cell size or a synaptic marker in 
HttQ111/+ mice through 12 months of age. (a) NeuN+ cell density is not changed between HttQ111/+ and Htt+/+ 
mice at 3, 9, or 12 months of age (three image frames analyzed per mouse). ANOVA: Genotype F(1, 100) = 0.03, 
p = 0.87, Age F(2, 100) = 98.9, p < 0.0001, Interaction F(2, 100) = 2.79, p = 0.07. Data presented as boxplots. (b) 
Distribution of striatal NeuN+ cell sizes does not differ between HttQ111/+ and Htt+/+ striata at 9 months of age. 
Two-sample K-S test D = 0.02, p = 0.98, N = 2038 cells, one image frame analyzed per mouse. (c) Synaptophysin 
staining intensity was examined at 3, 9, and 12 months of age, showing no differences between HttQ111/+ and 
Htt+/+ mice (one image frame analyzed per mouse). ANOVA: Genotype F(1, 93) = 3.7, p = 0.057, Age  
F(2, 93) = 16.7, p < 0.0001, Interaction F(2, 93) = 1.5, p = 0.22. Data presented as boxplots. (d) Glia counts at 12 
months show no difference in numbers of GFAP+ astrocytes (green; t(32) = 1.2, p = 0.25.) and Aif1+ microglia 
(red; t(31) = 0.2, p = 0.9) in HttQ111/+ versus Htt+/+ striata. Representative Htt+/+ section shown. Data presented 
as boxplots.
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study with 10 animals per arm (4 arms - Htt+/+ and HttQ111/+ mice in a treatment or control arm). By 12 months of 
age, several individual endpoints provide reasonable power to detect this 50% rescue, including reductions in stri-
atal Scn4b mRNA levels and an increase in MW8-immunoreactive aggregate counts (Fig. 7a). We next considered 
whether combining information from multiple molecular endpoints would improve the power to detect a partial 
rescue. We trained an elastic net logistic regression model to classify HttQ111/+ versus Htt+/+ mice using a weighted 
combination of the QRT-PCR (Scn4b, Drd1a, Cnr1, Darpp32, Homer1) and IHC (mHTT aggregates, mHTT area, 
DARPP32, cell counts, neuronal ratio) endpoints in the striatum. This model distinguished HttQ111/+ vs. Htt+/+ 
mice with > 90% accuracy in training data from 9- and 12-month-old mice. The model assigns non-zero weights 
to 0 endpoints in 3-month-old mice, 9 in 9-month-old mice, and 9 in 12-month-old mice (regression coefficients 
for individual endpoints provided in Fig. 7d). With a sample size of 10, this multivariate model would have 
80% power to detect a 35% rescue in 12-month-old mice or a 60% rescue in 9-month-old mice (Fig. 7b). With 
n = 20, the model had 80% power to detect a 25% rescue in 12-month-old mice or a 40% rescue in 9-month-old 
mice (Fig. 7c). These results suggest that combining information from multiple molecular endpoints can improve 
power to detect subtle effects of treatments.
Figure 4. Progressive accumulation of p62 - and huntingtin-immunoreactive neuronal intranuclear 
inclusions (NIIs) in the striatum of aging HttQ111/+ mice. (a) Images of the dorsolateral striatum taken in  
5-μm sections of 12-month mice triple labelled for neurons (Red; NeuN), nuclei (Blue; DAPI) and aggregated 
huntingtin (Green; MW8). Accumulation of both large neuronal-nuclear HTT aggregates, as well as small 
huntingtin nuclear speckles is present in HttQ111/+, but absent in Htt+/+ mice. (b) Total neuronal nuclear MW8 
immunoreactivity increases from 3 to 9 months of age, before declining at 12 months of age (Kruskal-Wallis: 
H(5) = 80.7, p < 0.0001, Dunn: 3-month genotype p = 0.15, 9-month genotype p < 0.0001, 12-month genotype 
p < 0.0001; N = 108, breakdown in Table 1. (c) Using a neuronal (NeuN) mask with particle inclusion from 
0.5–5 μm2 shows a median of 10% of neurons contain large nuclear aggregates by 9-months, which increases 
to 27% at 12 months of age. The presence of NIIs provides a robust measure for huntingtin accumulation with 
an extremely robust effect size for genotype comparisons at 9- and 12-months (d = 1.6 and 6.7, respectively; 
error bars = 95% confidence interval). Kruskal-Wallis: H(5) = 87.9, p < 0.0001, Dunn: 3-month genotype p = 1, 
9-month genotype p < 0.0001, 12-month genotype p < 0.0001; N = 108, breakdown Table 1. (d) Images co-
labelled for aggregated huntingtin (Green; MW8), and autophagy adaptor protein p62 (Red), demonstrate p62 
is colocalized with aggregated huntingtin in 12-month HttQ111/+ mice.
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Discussion
We have here characterized the health and progression of phenotypes in the HttQ111/+ mouse, which accurately 
model the zygosity and Htt expression level of human HD patients. We found that, in contrast to transgenic 
N-terminal HTT fragment models of the disease, which have rapidly progressing and terminal disease, the 
HttQ111/+ mice were grossly healthy through 12 months of age in terms of body weight, plasma chemistry and both 
central and peripheral inflammation, extending previous observations of these mice10. Despite their generally 
healthy state in their first year of age, during this interval they presented striatal-specific, progressive, molecular 
changes consistent with those observed in other animal models of HD and indeed human mutation carriers, as 
well as specific behavioral phenotypes consistent with early HD. Using simulation studies, we demonstrated that 
these animals provide a powerful tool for experimental therapeutics targeting these early molecular changes.
In a recent review, Menalled and Brunner11 demonstrated that less than 5% of preclinical studies of reviewed 
therapeutic agents in HD were tested in knock-in models of the disease. The R6 and N171 lines of mice, which 
transgenically express short fragments of mHtt, were much more commonly used, together comprising 72% of all 
preclinical studies examined. Translation from animal models of neurodegeneration to human clinical trials has 
been disappointing, with a large number of agents predicted to be useful in transgenic animals failing to provide 
clinical benefit in human HD, for example11. A major benefit of screening therapeutics in short fragment mouse 
models of HD is that they present robust behavioral phenotypes, including motor alterations, affective impair-
ments and cognitive alterations4. Similar, though less pronounced, phenotypes have been observed in full-length 
YAC128 and BACHD mice9. Distinguishing central effects from peripheral ones is difficult in these animals 
because they either progressively lose (e.g. R6/234 and N17134,35) or gain (YAC12836 and BACHD9) significant 
amounts of body weight in parallel with the development of progressive molecular and behavioral phenotypes. 
Large observational studies have suggested that HD patients may, on average, lose weight9,37, as observed in short 
fragment mouse models of HD. However, more recently, careful and well-powered studies of presymptomatic HD 
mutation carriers and early stage patients reveals they have normal body composition and plasma chemistry38, 
consistent with our observations in aging HttQ111/+ mice (Table 1).
While presymptomatic HD mutation carriers do not show clinically obvious motor impairments, by defini-
tion, they do show clear sub-clinical cognitive impairments39 and progressive affective alterations. Amongst affec-
tive changes in HD mutation carriers, apathy has emerged as the most widely observed40, and uniquely amongst 
neuropsychiatric symptoms, progresses in a continuous fashion with disease state40,41. Like presymptomatic HD 
mutation carriers, previous studies of HttQ111/+ mice revealed normal gross motor behavior and grip strength 
through 12 months of age9,10,42. Recent work with q175 HD knock-in mice suggests they present subtle moti-
vational alterations detected using mixed fixed-/progressive-ratio operant tasks43. Similarly, reduced executive 
function has been observed in HttQ111/+ mice using delayed non-match to sample tasks42. The data presented here 
(Fig. 6) suggest that 9-month old HttQ111/+ mice do not have enhanced anxiety or depression-like behaviors, but 
do show motivational deficits, most notably a reduced performance on a fixed-ratio 1 task, despite normal hedonic 
drive for sweet stimuli at this time point. These behavioral studies, in conjunction with the body weight and 
Figure 5. Histological analysis confirms protein-level reductions in DARPP32 in the aging HttQ111/+ 
striatum. (a) DARPP32 staining with NeuN positive cell traces (Yellow) to demonstrate the inclusion areas 
for DARPP32 quantification (Top). Representative images of DARPP32, NeuN, and DAPI triple-labelled 
dorsolateral striatum highlights interneurons (Red), medium spiny neurons (MSN; Yellow), and non-
neuronal cells (Blue). B. DARPP32 immunofluorescence per neuronal cell body is reduced in HttQ111/+ mice 
by 12-months (Fig. 5; Kruskal-Wallis: H(5) = 19.6, p = 0.0015, Dunn: 3-month genotype p = 0.12, 9-month 
genotype p = 0.09, 12-month genotype p = 0.006, N = 108, breakdown in Table 1). Data are presented as 
boxplots, effect size error bars = 95% confidence interval.
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general health data presented here, suggest that HttQ111/+ mice more closely resemble pre-symptomatic mutation 
carriers than do short fragment models of HD. Importantly, this suggests interventions targeting apathy, the single 
most prevalent and progressive psychiatric manifestation of HD41,40, can be tested in knock-in models of HD.
Transcriptional dysregulation in HD has long been noted in both human samples and samples taken from 
experimental models. Here, using mRNA sequencing techniques we provide quantitative evidence about the 
degree to which striatal transcriptional changes exceed transcriptional changes in a relatively spared tissue in HD, 
the cerebellum. Indeed, at 9 months of age, the striatum has more than 250-fold more differentially expressed 
transcripts than does the cerebellum at this age (Fig. 1A). This is consistent with the fact that the cerebellum 
is grossly spared from pathological volume change in both human patients24 and full-length mouse models of 
HD14. A concern with transcriptional changes in pathologically affected tissue is that tissue architecture changes 
(in either cellular composition or relative cell size changes) may explain alterations in mRNA abundance in tissue 
level analyses. The evidence presented here suggests that robust transcriptional dysregulation in the striatum of 
HttQ111/+ mice precedes any alterations in the density of striatal neurons, astrocytes, microglia or synapses. In fact, 
of the presented phenotypes, altered transcript levels are amongst the most powerful features for distinguishing 
Htt+/+ from HttQ111/+ mice at 9–12 months of age (Fig. 7). These data confirm that striatal transcriptional dysreg-
ulation occurs in the absence of changes in cell number in early HD, occurring the absence of neurodegeneration, 
gliosis or overt loss of synapses. Also consistent with previous observations of HttQ111/+ mice at younger ages17, we 
Figure 6. Presence of HttQ111 allele results in reduced reward seeking behavior independent of anxiety-like 
or depressive behavior. (a) HttQ111/+ mice display reduced reward attainment compared to Htt+/+ mice across 
three reinforcement durations (Rft = 40 ms, 60 ms, & 100 ms with 100 ms being 5 μL) during FR1 operant testing 
(Genotype: F(1,14) = 17.0, p = 0.001, Genotype x Reward: F(2,28) = 8.4, p = 0.001). (b) HttQ111/+ mice exhibit a 
stronger preference for sucrose pellets during the hours sucrose consumption task compared to Htt+/+ mice 
(Genotype: F(1,14) = 15.9, p = 0.001). (c) HttQ111/+ and Htt+/+ mice do not differ in the amount of time spent 
inactive during the Porsolt swim task. (d) HttQ111/+ and Htt+/+ mice spend a similar amount of time in the open 
arms of the elevated plus maze. (e) HttQ111/+ and Htt+/+ mice do not differ in the amount of time spent in the 
light compartment of the apparatus during the light/dark exploration task (a) and (b) are presented as mean 
+/− SEM. (c), (d) and (e) are presented as boxplots.
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Figure 7. Power analysis suggests multivariate endpoints maximize power for pre-clinical study. (a) 
Estimated power to detect a 50% rescue of individual endpoints in 3-, 9- or 12-month-old mice, assuming a 
sample size of 10 HttQ111+ mice and 10 Htt+/+ mice in baseline conditions and 10 HttQ111+ mice and 10 Htt+/+ 
mice given a hypothetical treatment that induces a partial rescue. (b,c) Power to detect partial rescue at each 
timepoint using a multivariate elastic net classifier and a sample size of 10 (b) or 20 (c) mice per group. (d) 
Regression coefficients (weights) assigned to each biomarker in the elastic net model. Positive and negative 
coefficients indicate that the marker is increased or decreased in HttQ111/+ mice, respectively.
www.nature.com/scientificreports/
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observe progressive striatal-specific accumulation of neuronal intranuclear inclusions (NIIs) in HttQ111/+ mice. 
Similar to aggregates found in human HD, these large inclusions are primarily restricted to neurons (we do not 
observe any glial NIIs), and co-stain with autophagic cargo marker p62 (Fig. 4). Our power analyses suggest that 
treatments that alter either mHTT levels, or improve proteostasis and thereby alter aggregate formation, can be 
robustly tested in vivo using the HttQ111/+ mice with adequate power.
While we find that the HttQ111/+ mice provide a number of useful reflections of human HD, there are also 
significant limitations to their truly modeling Huntington’s disease. First, even healthy captive mice live only 
approximately 2 years44, while human HD generally has onset only after 30–50 years of relatively unaffected 
life45. This discrepancy in lifespan may explain why very long CAG repeats (here, approximately 113 - Table 1) 
are required to lead to robust molecular or behavioral changes. Repeats of this length would be predicted to cause 
juvenile onset HD in the human context, with fulminant behavioral and neuropathological consequences that 
are not observed in any mouse models described46. Alternatively, or in addition, the different neural circuity47, 
transcriptional and proteomics networks6,48 of the human brain could explain the selective vulnerability of human 
neurons to mutant-huntingtin induced cell dysfunction and death.
In summary, we present data suggesting that the HttQ111/+ mice are grossly healthy during their first year of life, 
yet present a range of molecular and behavioral alterations consistent with presymptomatic HD mutation carri-
ers. Our power analyses revealed that these changes can provide sufficiently powered endpoints for preclinical 
studies of neuroprotective therapies for HD with a reasonable duration and number of subjects. In conjunction 
with other recently described cognitive and affective10,42,43 behavioral phenotypes in these animals, we propose 
that knock-in models provide greater face validity, and thereby potential translatability, than transgenic models 
of HD for future preclinical studies.
Methods
Mice. We used 4 cohorts (detailed below) of mixed-gender B6.HttQ111/+ mice for the described stud-
ies (Research Resource Identifier:IMSR\_JAX:003456). The creation of the HttQ111/+ line has been described5. 
Experiments for cohort 1 were conducted in accordance to NIH Guide for the Care and Use of Laboratory 
Animals and was approved by the Massachusetts General Hospital (MGH) Subcommittee of Research Animal 
Care (SRAC). Experiments for cohort 2 and 3 were conducted in accordance to NIH Guide for the Care and 
Use of Laboratory Animals and approved by the Western Washington University (WWU) animal care and use 
committee. Experiments for cohort 4 were conducted in accordance to the UK Animals (Scientific) Act 1986, 
European Union Directive 2010/63/EU and approved by the Cardiff University local ethical review committee.
Cohort 1 (RNA sequencing). The cohort used to generate the RNASeq data presented in Fig. 1 was gener-
ated at Massachusetts General Hospital (MGH). Cohorts of 58 total mixed-gender littermate mice (12 × 3-month 
and 16 × 9-month HttQ111/+; 12 × 3-month and 16 × 9-month Htt+/+) mice were generated by crossing 
B6.HttQ111/+ males with C57Bl/6 J females. The size of the Htt CAG tract ranged from 126 to 135 (mean 131), with 
no significant differences observed across the groups of this cohort. The mice were part of a larger study of the 
impact of dietary fat on metabolism49 - the mice described in Fig. 1 were fed chow from weaning until 9 months of 
age with either 60% kcal/fat (Open Source Diet D12492) or 45% kcal/fat (Open Source Diet D1245). Striatal and 
cerebellar transcriptional effects of these diets were collapsed for the analysis presented in Fig. 1.
Cohort 2 (Molecular natural history). The cohort used to generate the molecular natural history data, 
presented in Figs 2–5 and 7, was bred and maintained at the Jackson Labs (Bar Harbor, Maine) and shipped to 
the WWU vivarium approximately 2 weeks before the endpoints under investigation. Three groups of mice were 
sacrificed at 3 (90 ± 4 days), 9 (295 ± 2 days) or 12 (369 ± 5 days) months of age (Table 1).
Cohort 3 (Behavioral cohort, WWU). The cohort used to collect the behavior data at WWU (Porsolt 
swim test, elevated plus maze, light/dark box, sucrose solution preference) were bred and maintained at Jackson 
Labs (Bar Harbor, Maine) and consisted 40 female mice (20 Htt+/+; 20 HttQ111/+). Htt CAG tract ranged from 107 
to 119 (mean 114). Mice were shipped to the WWU vivarium at 8 months of age and acclimated to reversed light 
cycle conditions (lights on from 12 am to 12 pm) for four weeks prior to testing at 9 months of age. Behavioral 
assays were conducted between 1:00 pm and 5:00 pm during the active phase.
Cohort 4: (Behavioral cohort, Cardiff). The Cardiff cohort consisted of 16 mice (8 Htt+/+; 8 HttQ111/+), 
bred in-house from founders originally obtained from Jackson Labs (Bar Harbor, Maine), was used for the FR1 
and sucrose pellet preference experiments. The mice were housed under 12-hour light/dark cycle with free access 
to food and water outside of experimental periods. FR1 operant testing began when the mice were 4 months of 
age, followed by the sucrose pellet preference experiment at 6 months of age. All experimental procedures were 
initiated between 8 am and 9 am.
Tissue isolation and sample processing. After a three hour fast, mice in the molecular natural history cohort 
were euthanized via IP sodium pentobarbital injection (Fatal Plus, Henry Schein). Whole blood was collected 
by cardiac puncture with EDTA (25 μM) and plasma was extracted. Mice were then transcardially perfused with 
phosphate buffered saline (PBS) to clear tissues of blood. Whole brains were extracted and placed in a Brain Slicer 
Matrix (Zivic). A midline longitudinal cut was made to separate hemispheres. Coronal cuts were made in the left 
hemisphere 1- and 4-mm posterior to the junction between the olfactory bulb and cortex, resulting in a 3-mm 
thick corticostriatal block of tissue (Figure S2) that was formalin fixed (6–8 hours), paraffin embedded, sectioned 
(5-μm), and mounted onto glass slides for immunohistochemistry. The contralateral hemisphere was dissected 
into striatum, cortex, and cerebellum, and flash frozen for molecular analyses.
www.nature.com/scientificreports/
13Scientific RepoRts | 7:41570 | DOI: 10.1038/srep41570
Plasma chemistry and immune profiling. Plasma clinical chemistry was measured using an AU2700 Chemistry 
Analyzer (Beckman Coulter) at Phoenix Central Laboratories (Mukilteo, WA, USA). A panel of 37 cytokines, 
chemokines and acute phase reactants was assessed using a multiplexed cytometric bead array immunoassay 
(Mouse InflammationMAP 1.0, Myriad RBM, Inc., Austin, TX, USA).
Library construction, RNA Sequencing and RNASeq analysis. For the RNA Sequencing studies in 
Fig. 1, RNA was extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen). Quality control for RNA was con-
ducted using the Agilent 2100 Bioanalyzer with Agilent RNA 6000 Nano kit. Libraries for sequencing were con-
structed using the Illumina TruSeq RNA Sample Prep Kit and sequenced on a HiSeq 2000 (2 × 50 bp) to a read 
depth of 2.4 × 107 ± 6.2 × 106 per sample. The fastq files were aligned using the default parameters of SNAPR50 
(https://github.com/PriceLab/snapr) against the GRCh38 genome assembly, along with the transcriptome assem-
bly gtf file from Ensembl, GRCh38.75. SNAPR generates read counts for both genes and transcripts simultane-
ously with alignment. All alignments were performed on Amazon EC2 c3.8xlarge instance using a Ubuntu14.04 
base AMI. Differential gene expression was conducted using the edgeR package51, and pathway enrichment using 
HTSanalyzeR52 in Bioconductor53.
mRNA quantification – QRT-PCR. Total RNA was extracted from the right hemi-striatum using the RNeasy 
Lipid Tissue Mini Kit (Qiagen). Tissue was homogenized in 500 μL of Qiazol Lysis Reagent for one minute at 
4,000 rpm using a homogenizer (BeadBug; Benchmark Scientific). Aqueous and organic phases were separated 
by the addition of 100 μL of chloroform. All subsequent steps in were performed according to the manufac-
turer’s protocol. Reverse transcription was performed using the Superscript III First Strand Synthesis System 
(Life Technologies) following the manufacturer’s protocol. Quantitative real-time polymerase chain reaction 
(QRT-PCR) was conducted with the resulting cDNA using the Real-Time StepOne System (Applied Biosystems). 
Transcripts were analyzed by the relative quantitation standard curve method and normalized to a transcript 
unregulated by mutant Htt expression (Actb). All taqman probes were purchased from Life Technologies and 
were as follows: Drd1a: Mm02620146\_s1, Drd2: Mm00438545\_m1, Cnr1: Mm01212171\_s1, Darpp32: 
Mm00454892\_m1, Penk: Mm01212875\_m1, N4bp2: Mm01208882\_m1, Islr2: Mm00623260\_s1, Pde10a: 
Mm00449329\_m1, H60b: Mm04243254\_m1, and Scn4b: Mm01175562\_m1.
Immunohistochemistry. Deparaffinization washes were as follows: 2 × 3 min xylenes, 3 min xylenes:ethanol (1:1), 
3 min 95% ethanol, 3 min 80% ethanol, 3 min 70% ethanol, 3 min 50% ethanol, H2O rinse. Heat-mediated antigen 
retrieval: 20 min at 95 °C in citrate buffer (pH 6) or Tris-EDTA buffer (pH 9). Sections were blocked in 20% goat 
serum in PBS for 1 hour, followed by overnight incubation in primary antibody at 4 °C; GFAP-stained slides were 
blocked with a mouse-on-mouse kit (Vector). Following wash, secondary antibody incubation was 1 hour at room 
temperature. Slides were mounted and sealed with DAPI fluormount-G (Southern Biotech). AIF1 slides were 
prepared from free-floating 40-μm coronal sections. Primary antibodies: mouse anti-aggregated HTT (1:750; 
DSHB; MW8), mouse anti-SQSTM1/p62 (1:300; Abcam; AB56416), rabbit anti-NeuN (1:750; Millipore; ABN78), 
mouse anti-DARPP32 (1:250; SCBT; H-3; sc-271111), rabbit anti-AIF1 (1:500; Wako), mouse anti-GFAP (1:500; 
Millipore; MAB3402). Secondary antibodies: Alexa 488 anti-mouse (1:1000; Life Technologies), Alexa 568 
anti-rabbit (1:1000; Life Technologies).
Image acquisition and analysis. For all immunolabeled sections, 12-bit images were acquired with an IX-81 
laser-scanning confocal microscope with Fluoview 1000 software (Olympus) using a 60x/1.42 NA oil objective, 
with the exception of AIF/GFAP which used a 40x/1.30 NA oil objective. For each secondary antibody, acquisi-
tion parameters were set such that a brain section with no primary antibody emitted no fluorescent signal and 
settings were maintained for the entire set of sections. Z-stack numbers and thickness were kept consistent for 
each set of sections. Maximum z-projections were compiled using ImageJ54. NeuN and/or DAPI masks were 
automatically created using ImageJ default thresholds, and used to measure neuronal and/or nuclear expression 
of MW8, p62, and DARPP32 (Fig. 5B). AIF1 and GFAP were manually counted. Synaptophysin was quantified as 
percent area of image with synaptophysin immunoreactivity. Experimenters were blind to genotype for antibody 
application, image acquisition, and analysis.
Behavior. Elevated Plus Maze. The plus maze was made of white acrylic with two open arms (25x5 × 0.5; 
room lux ~475) and two closed arms (25x5 × 16 cm) extending from a central platform elevated 50 cm above 
the floor. Each session began by placing a mouse in the intersection of the arms with its head directed toward 
the closed arm located opposite of the experimenter and ended after 10 minutes of free exploration. Activity was 
video recorded and analyzed using EthoVision XT 8 (Noldus).
Light/Dark Exploration. The light/dark exploration box used in this experiment was constructed of acrylic plas-
tic divided into a clear, brightly illuminated side (27 × 27 × 30 cm; room lux ~475) and a black, fully enclosed side 
(18 × 37 × 30 cm) separated by a 5.5 × 5.5 cm opening that permitted the animals to move freely between each 
compartment. Each trial began by placing a mouse in the illuminated section of the apparatus facing the entrance 
to the dark section, and ended after 10 minutes of free exploration. Activity was video recorded and analyzed 
using EthoVision XT 8 (Noldus).
Porsolt Swim Test. Mice were placed into a clear 8-quart bucket (28 cm tall, 22 cm in diameter) filled ¾ full with 
room temperature water. Each mouse was placed into the bucket for a single 6-minute session, and swimming 
activity was recorded using a camera mounted on a tripod oriented toward the side of the apparatus. Inactivity 
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during the last 4 minutes of each session was assessed by two separate experimenters blind to genotype (interrater 
reliability = 0.89), and a single composite score was calculated for subsequent analyses.
Sucrose Consumption Test. Mice were given a sucrose eating challenge to determine whether free access to 
sucrose would produce different levels of consumption between the genotypes. For these sessions the mice were 
given 95% sucrose pellets (AIN-76A, TestDiet, Richmond, IN) for 10 hours per day for 4 days, and normal lab 
chow for 14 hours. The amount of sucrose and chow consumed was measured daily by weight of 5 mg sucrose 
pellets/chow consumed and expressed as g/kg of bodyweight.
Sucrose Preference Test. Two-bottle sucrose preference testing occurred in the WWU vivarium over eight days. 
On day 1, animals were single housed and provided access to two identical 50 mL dual bearing sipper tubes 
containing tap water. On day 2, one of the tap water tubes was replaced with a 2% sucrose solution, and mice 
were provided free access to both sipper tubes for 72 hours. On day 5, the sipper tube containing the 2% sucrose 
solution was replaced with a 4% sucrose solution, and mice were provided free access for another 72 hours. The 
location of the sipper tube containing sucrose solution relative to tap water was counterbalanced between exper-
imental animals and rotated each day to avoid place preference. Every 24 hours, experimenters weighed both 
sipper tubes to determine consumption from each. The amount consumed from each tube was expressed as a 
percentage total consumption per day; average consumption for each sipper tube during each 72-hour period 
was compared between genotypes
Operant Testing. Operant testing was conducted in 16 aluminium/steel 9-hole box (14 cm × 13.5 cm × 13.5 cm) 
operant chambers (Campden Instruments, UK). On the rear wall of each chamber situated 15 mm from the grid 
floor, a horizontal 9-hole light array was fixed that had 9 response holes (11 mm diameter and 2 mm apart) that 
contained lights at the rear and infra-red (IR) sensors at the front, such that nose poke responses to light stimuli 
could be detected with an IR beam break. For the present experiments only the central response hole (hole 5 of 9) 
was used with the other holes blocked. On the inner of the front wall a food magazine was placed that allowed the 
mouse to recover sweet liquid rewards (Yazoo strawberry milk, Campina Ltd, UK), delivered by peristaltic pump 
after a successful response to the light stimuli. Initial training consisted of non-contingent reward presentations 
to the magazine that were signalled by the illumination of a light in the magazine. Removal of the head from the 
magazine was detected by an IR beam across the magazine entrance which then reset the trail. This was followed 
by training the mice to respond with a nose poke to illuminated hole 5 on the light array. A response in lit hole 5 
extinguished the light and illuminated the magazine light to signal reward delivery. On removal of the head from 
the magazine, the magazine light was extinguished and after a 2 s intertrial interval, a new trial began with the 
illumination of the stimulus light in hole 5 thereby continuing the fixed ratio 1 (FR1) schedule of reinforcement. 
Once all mice could successfully complete 30 trials in a 30 minute session, the reward seeking probes began. Nine 
45 minute FR1 sessions were run using, 3 (x3) counterbalanced reward pump durations (40 ms, 60 ms, 100 ms), 
to determine sensitivity to different reward magnitudes with the key outcome measure being number of rewards 
obtained.
Statistical Analysis. Statistics were processed in R 3.2.355. Data were tested for normality (Anderson-Darling 
test)56 and homoscedasticity (Levene’s test)57. If data met parametric assumptions, we fit linear models analysed 
by ANOVA. If data violated these parametric assumptions, Kruskal-Wallis test was used as an omnibus test and 
followed up with Dunn’s test to determine whether pairwise differences between genotypes were significant with 
Bonferroni corrections for multiple post-hoc comparisons. Data presented in Figs 2–6 used boxplots - horizontal 
lines indicate 25th, 50th and 75th percentile, while the vertical whiskers indicate the range of data. Data falling 
outside 1.5 times the interquartile range are graphed as isolated points, but were not excluded from statistical 
analysis58. Simulated distributions for power analysis were constructed with the mvrnorm function in the MASS 
package59,60. The elastic net classifier was constructed using glmnet59. Endpoint QRT-PCR and IHC data and code 
for power analysis are available at https://github.com/seth-ament/hd_endpoints. Graphics were produced using 
ggplot261 and Illustrator (Adobe).
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